FATE Therapeutics (FATE) executive compensation, 2026 proxy

Bahram Valamehr, Ph.D., MBA, President, Chief Executive Officer and Director, was paid $2.2M in 2025, down 37% from $3.6M the year before.

Filed
April 24, 2026
Annual meeting
June 12, 2026
Pay year
2025
Named executives
3
CEO total pay
$2.2M-37% vs prior year
CEO Target Bonus
60%Percentage of annual base salary
CFO Salary
$495,000Annualized base salary
Legal Officer Salary
$520,000Annual base salary

How MBA was paid

$2.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary27%Option awards57%Non-equity incentive16%All other compensation0%

Named executive officers

ExecutiveTotal
Bahram Valamehr, Ph.D., MBAPresident, Chief Executive Officer and Director$2,248,568
Kamal Adawi, M.S., MBAChief Financial Officer and Treasurer$714,800
Cindy R. Tahl, J.D.Chief Legal & Compliance Officer and Corporate Secretary$1,111,996

What changed and why

  • $2.2MBahram Valamehr total compensation decreased to $2,248,568 following his promotion to President and CEO.
  • $600KBahram Valamehr received a base salary of $600,000 for fiscal 2025.
  • $360KBahram Valamehr received a non-equity incentive payout of $360,000 representing target achievement.
  • Bahram Valamehr equity award for 2025 consisted solely of stock options.
  • Kamal Adawi joined the company as Chief Financial Officer and Treasurer effective October 20, 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.